KBRA Assigns Preliminary Ratings to Ares European Direct Lending CLO 2 Sarl February 23, 2026 KBRA UK (KBRA) assigns preliminary ratings to six classes of Notes issued by Ares European Direct Lending CLO 2 Sarl, a cash flow collateralized loan obligation (CLO) backed by a diversified portfolio of middle market corporate loans. This transaction is a multicurrency European middle market CLO. Ares European Direct Lending CLO 2 Sarl is managed [...]
LRN Welcomes Jean Brody as Chief Marketing Officer February 23, 2026 Brody’s appointment marks LRN’s third C-Suite addition in recent months, signaling organizational and leadership growth
Orbia Honored as a Top Company in its Industry in the S&P Global Sustainability Yearbook for Fifth Consecutive Year February 23, 2026 Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*), has been named a member of the S&P Global Sustainability Yearbook for the fifth consecutive year, which honors best-in-class global sustainability companies evaluated through the S&P Global Corporate Sustainability Assessment (CSA). “Orbia’s continued inclusion in this leading sustainability ranking underscores our conviction that sustainability is a driver [...]
Rudding Park Selects Agilysys Hospitality Software Solutions to Modernise Guest Journeys and Streamline Operations Across Its Hotel Ecosystem February 23, 2026 The award-winning resort will deploy a unified Agilysys technology platform to replace disconnected systems, enabling seamless guest recognition and operational efficiency across its hotel, spa, golf, and dining amenities.
BSE (formerly Bombay Stock Exchange) Selects ITRS to Strengthen Real-Time Monitoring and Operational Resilience February 23, 2026 Asia’s Oldest Stock Exchange Partners with ITRS to Strengthen Monitoring and Compliance
Ares Management Prices European Direct Lending CLO II at Over €300 Million February 23, 2026 Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely [...]
Compass Pathways Announces Pricing of $150 Million Public Offering February 23, 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants [...]
TNS Launches TNSPay SmartRoute to Put Merchants and Acquirers in Control of Payment Routing February 23, 2026 New intelligent routing gives payments teams the power to set the rules, automate failover and keep revenue flowing – backed by global scale and enterprise-grade security.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
Options Announces 15 Consecutive Years of SOC Compliance, Underlying Its Commitment to Delivering Secure Reliable Solutions February 23, 2026 Options Technology (Options), the leading provider of IT infrastructure to global financial institutions, today announced that it has achieved SOC compliance for the 15th consecutive year, adhering to Type 2 SOC 1 & ISAE 3402, Type 2 SOC 2, and Type 2 SOC 3 standards. Danny Moore, President and CEO at Options said, “From the [...]